Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Size: px
Start display at page:

Download "Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)"

Transcription

1 Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis

2 Comparison of Four Chemotherapy Regimens for Advanced Non Small-Cell Lung Cancer Schiller et al. NEJM 2002; 346: 92-98

3 NSCLC: l avenir? La chimiothérapie à la carte Les thérapies ciblées

4 Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non Small-Cell Lung Cancer NEJM 2004; 350:

5 DNA Repair by ERCC1 in Non Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy NEJM :

6 Vinorelbine plus Cisplatin vs. Observation in Resected Non Small-Cell Lung Cancer NEJM 2005; 352:

7 Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer observation observation p53 p53 IHC IHC > > p53 IHC < J Clin Oncol 2007; 25: 5240

8 A Genomic Strategy to Refine Prognosis in Early-Stage Non Small-Cell Lung Cancer NEJM 2006; 355:

9 Cell 2000; 100: 57-70

10 Structure schématique des Récepteurs de la famille ErbB Bull Cancer 2006; hors série: 17-24

11 Bull Cancer 2007; 94 (Suppl FMC): F

12 Bull Cancer 2006; hors série: 17-24

13 Bull Cancer 2006; hors série: 17-24

14 Les récepteurs ErbB en tant que cibles «multi-sites» Récepteurs ErbB EGFR VEGF et VEGF-R les NIB les MAB les NIB les MAB Autres inhibiteurs erlotinib (Tarcéva ) cétuximab (Erbitux ) sorafénib (Nexavar ) bévacizumab (Avastin ) Thalidomide géfitinib (Iressa ) panitumumab (Vectibix ) sunitinib (Sutent ) Inhibiteurs des valatanib métalloprotéinases vandétanib Autres

15 Quelques exemples de molécules ciblant les récepteurs erbb

16 Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non Small-Cell Lung Cancer: A Phase III Trial INTACT 2 J Clin Oncol 2004; 22:

17 Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non Small-Cell Lung Cancer: A Phase III Trial INTACT 2 J Clin Oncol 2004; 22:

18 Erlotinib in Previously Treated Non Small-Cell Lung Cancer Previously treated pts after 1 or 2 lines chemotherapy n = 731 Erlotinib 150 mg / j Placebo NEJM 2005; 353:

19 Erlotinib in Previously Treated Non Small-Cell Lung Cancer NEJM 2005; 353:

20 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2005; 366:

21 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2005; 366:

22 Comparison of hazard ratios from ISEL and BR21

23 Why gefitinib failed? Nature Reviews Cancer 7,

24 Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST).

25 Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). gefitinib docetaxel n ORR (%) 9,1 7,6 HR = 1,22 (95%CI: 0,82 1,84) Median survival (mo) 7,6 8 1-year survival (%) HR = 1,02 (95%CI: 0,905 1,150) PFS (mo) 2,2 2,7 6 mo PFS (%) HR = 1,04

26 Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). gefitinib docetaxel Adverse event (%) 72,3 82,2 Serious adverse event (%) 3,2 18,2 Décès iatrogène (%) 0,8 2,1 Rash (%) 49,4 10,2 Diarrhée (%) 35 24,8 Alopécie (%) 3,2 35,5 Neurotoxicité (%) 6,7 23,9 Neutropénie fébrile (%) 1,2 10,1 Dry skin (%) 15,2 1,4 Conclusion: géfitinib, le retour?

27 Études de phase II évaluant le géfitinib ou l erlotinib chez des patients atteints d un CBNPC avec mutation de l EGFR

28 «Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer». 99 patients, randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (AUC = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32) treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months) bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns: minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. J Clin Oncol 2004;22:2184

29 Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. previously untreated NON-SQUAMOUS NSCLC stage IIIB/IV pas d'hémoptysie macroscopique PS = 0/1 pas de pathologie thrombo-embolique ou hémorragique pas de métastase cérébrale P 200 mg/m2+ C AUC=6 every 3 weeks P 200 mg/m2+ C AUC=6 every 3 weeks + B 15 mg/kg d1 every 3 weeks n = 444 n = 434 Abst 4, ASCO 2005

30 Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. IIIB 14 % 13 % neutropénie 16,4 % 24 % PC PCB p hémorragie 0,3 % 4,5 % < 0,01 HTA 0,7 % 6 % < 0,01 n tox grade (5 hémoptysies) CR 0 % 1,4 % PR 10 % 25,8 % ORR 10 % 27,2 % < 0,0001 PFS 4,5 mois 6,4 mois < 0,0001 MS 10,2 mois 12,5 mois 0, yr s 43,7 % 51,9 % 2-yr s 16,9 % 22,1 %

31 Paclitaxel Carboplatin Alone or with Bevacizumab for Non Small-Cell Lung Cancer Sandler et al. NEJM 2006; 355:

32 Paclitaxel Carboplatin Alone or with Bevacizumab for Non Small-Cell Lung Cancer Sandler et al. NEJM 2006; 355:

33 Paclitaxel Carboplatin Alone or with Bevacizumab for Non Small-Cell Lung Cancer Sandler et al. NEJM 2006; 355:

34 Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. «PCB is now the ECOG reference standard for first line treatment of advanced non squamous nonsmall cell lung cancer»!!!

35 Science 2002; 297: 63-64

36 NSCLC stade IV: évolution schématique de la survie au fil du temps

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

Treatment Paradigm in NSCLC Treatment

Treatment Paradigm in NSCLC Treatment Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer

Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,

More information

Thorakale Onkologie. ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013

Thorakale Onkologie. ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013 Triple negativ Thorakale Onkologie ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013 Driver Oncogene Mutations in non sq-nsclc Genome Res. 2012 November; 22(11): 2109 2119 8021: Detection of EGFR-activating

More information

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,

More information

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer

More information

( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth

( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth 2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years

SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Treatment of Stage IV Non-small Cell Lung Cancer

Treatment of Stage IV Non-small Cell Lung Cancer CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Lung cancer is the leading cause of cancer-related death in the United

Lung cancer is the leading cause of cancer-related death in the United Evolving Treatment Paradigms in Non-Small Cell Lung Cancer MARGARET E. M. VAN METER, MD Medical Oncology Fellow Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston,

More information

Evolving Treatment Paradigms in Non-Small Cell Lung Cancer

Evolving Treatment Paradigms in Non-Small Cell Lung Cancer PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICE NEWS.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer CALEB T. CHU, MD, MPH Postdoctoral Fellow Department of Thoracic/Head and Neck Medical Oncology

More information

non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas

non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas Adjuvant chemotherapy for non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas células Daniel B. Costa, MD, PhD, MMSc Division i i of Hematology/Oncology l Beth Israel

More information

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014

Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014 Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!

More information

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare

More information

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? 4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date

KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013

More information

Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer

Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare

More information

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1

More information

Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status

Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status Tracey L. Evans, MD Abstract In spite of advances in molecular profiling

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

EGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004

EGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004 Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D. Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Highlights in NSCLC From the 15th World Conference on Lung Cancer

Highlights in NSCLC From the 15th World Conference on Lung Cancer January 214 Volume 12, Issue 1, Supplement 1 A SPECIAL MEETING REVIEW EDITION Highlights in CLC From the 15th World Conference on Lung Cancer A Review of Selected Presentations From the 15th World Conference

More information

MAINTENANCE CHEMOTHERAPY

MAINTENANCE CHEMOTHERAPY 1 MAINTENANCE CHEMOTHERAPY FOR ADVANCED NSCLC Dr.M.V.Nagarjuna OBJECTIVES OF THIS SEMINAR 1. Definitions 2. Switch maintenance 3. Continuation Maintenance 4. Immunotherapy as maintenance 5. Conclusions

More information

NON-SMALL CELL LUNG CANCER STAGE IV

NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER STAGE IV Effective Date: November, 2013 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor

More information

Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC

Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC Martin J. Edelman, MD 1 Educational Objectives Review efficacy and safety data for current and emerging targeted agents and chemotherapy

More information

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

(1)Faivre-Finn C, Bouvier AM, Mitry E et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?

(1)Faivre-Finn C, Bouvier AM, Mitry E et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Colorectal cancer Chemotherapy for the elderly Dr Christophe TOURNIGAND Hôpital Saint Antoine France Hôpital Charles Lemoyne - Quebec GERCOR EPOG - UPMC Colorectal cancer ( CRC) : an Elderly Disease 3rd

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Immuno-Oncology 2015: A New Landscape in Lung Cancer

Immuno-Oncology 2015: A New Landscape in Lung Cancer Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)

More information

Lung Cancer Research: From Prevention to Cure!

Lung Cancer Research: From Prevention to Cure! Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology

More information

Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers

Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April

More information

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough?

New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? F. Cardoso, MD Champalimaud Cancer Center Lisbon, Portugal BBM 2010 Thank you to A Tutt & PRIME Oncology

More information

cure toadvances in Lung Cancer A Patient s Guide

cure toadvances in Lung Cancer A Patient s Guide A Patient s Guide toadvances in Lung Cancer The Biology of Lung Cancer New Methods for Detection The Latest Treatment Options Questions to Ask Your Doctor Resources cure C ancer U pdates, R esearch & E

More information

Third-line therapy in advanced non-small cell lung cancer

Third-line therapy in advanced non-small cell lung cancer JBUON 3; (): 99-97 ISSN: 7-65, online ISSN: -693 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Third-line therapy in advanced non-small cell lung cancer Zhen Ying Geng,, Shun Chang

More information

Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens

Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens VOLUME 32 NUMBER 18 JUNE 20 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens Alona Zer and Natasha

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Targeterbare mutationer / biomarkører Status og udfordringer for patologien

Targeterbare mutationer / biomarkører Status og udfordringer for patologien Targeterbare mutationer / biomarkører Status og udfordringer for patologien Birgit Guldhammer Skov overlæge, dr.med. Patologi afdelingen Rigshospitalet Biomarkers lung cancer Last 3-5 years More and more

More information

Pulmonary and Critical Care Regional Symposium April 25, 2015

Pulmonary and Critical Care Regional Symposium April 25, 2015 Pulmonary and Critical Care Regional Symposium April 25, 2015 2015: Molecular Medicine, Resistance Mutations and Immunotherapy. Keeping Up With The Latest in NSCLC Barbara J. Gitlitz MD Associate Professor

More information

The Platinum Salts in the Treatment of Triple Negative Breast Cancer

The Platinum Salts in the Treatment of Triple Negative Breast Cancer The Platinum Salts in the Treatment of Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, USA eric_winer@dfci.harvard.edu The Platinum Salts Old

More information

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with

More information

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer Review Article 2012 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran ISSN: 1735-0344 Tanaffos 2012; 11 (1): 12-17 TANAFFOS Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Câncer de Pulmão. Benefício e emprego das novas drogas. XIV Congresso da Sociedade Brasileira de Radioterapia

Câncer de Pulmão. Benefício e emprego das novas drogas. XIV Congresso da Sociedade Brasileira de Radioterapia + Câncer de Pulmão Benefício e emprego das novas drogas XIV Congresso da Sociedade Brasileira de Radioterapia Maikol Kurahashi, MD. Oncologia Clínica Hospital Santa Casa de Curitiba Declaração de conflitos

More information

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally

More information

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 Erlotinib and gefitinib for treating non- small-cell lung cancer that has progressed after prior chemotherapy Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 NICE 2015.

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Lung Cancer: New Biological Insights and Recent Therapeutic Advances

Lung Cancer: New Biological Insights and Recent Therapeutic Advances CA CANCER J CLIN 2011;61:91 112 Lung Cancer: New Biological Insights and Recent Therapeutic Advances Suresh S. Ramalingam, MD 1 ; Taofeek K. Owonikoko, MD, PhD 2 ; Fadlo R. Khuri, MD 3 Abstract Approximately

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,

More information

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer John delcharco, MD (Statistics based on CVMC data 2009-2013) Statistics Lung cancer is the leading cause of cancer deaths in the United States. The American Cancer Society estimates

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application

More information

PARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center

PARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair

More information

Novel Therapies and Side-Effect Management

Novel Therapies and Side-Effect Management TREATING THE PATIENT WITH METASTATIC NON SMALL- CELL LUNG CANCER Novel Therapies and Side-Effect Management Provided through an unrestricted educational grant by Genentech BioOncology and OSI Oncology

More information

Treatment for Lung Cancer: Drug Therapy

Treatment for Lung Cancer: Drug Therapy Treatment for Lung Cancer: Drug Therapy Living in the Molecular Age: Advances Drug Therapy of Lung Cancer John C. Morris, M.D. Division of Hematology-Oncology November 1, 2014 Non-small cell lung cancer:

More information

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating?

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating? Dr Peter Briggs Medical Oncologist Lung Cancer & Mesothelioma: is it worth treating? GOALS OF CANCER THERAPY CURE Good chance Medium chance Low chance PALLIATION Life prolonging Symptomatic improvement

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Sorafenib. Bernard ESCUDIER Institut Gustave Roussy Villejuif, France

Sorafenib. Bernard ESCUDIER Institut Gustave Roussy Villejuif, France Sorafenib for renal cell carcinoma Bernard ESCUDIER Institut Gustave Roussy Villejuif, France Renal Cell Carcinoma: Drugs and Targets pvhl = HIFα CCI-779 Bevacizumab VEGF KDR PDGF PDGFR TGFα EGFR Sunitinib,

More information

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice Lung Cancer: Integrating Targeted Therapies into Practice Table of Contents Program Information... 2 Faculty Biographies... 3 Genomic Profiling of NSCLC for EGFR Inhibitors... 4 Fred R. Hirsch, MD, PhD

More information

National Clinical Trials Network Groups Update Fall 2014

National Clinical Trials Network Groups Update Fall 2014 National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)

Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:

More information